Your search for non small cell lung cancer returned 26 results

Active Filters

Click on a filter below to refine your search. Remove a filter to broaden your search.

Drugs in the Pipeline remove

Your search for non small cell lung cancer returned 26 results

Sort Results:

Relevant Recent
Drugs in the Pipeline

PARP Inhibitor Veliparib Gets Orphan Drug Status from FDA

AbbVie announced that the Food and Drug Administration (FDA) has granted Orphan Drug Designation to veliparib, an investigational combination with chemotherapies or radiation for the treatment of advanced squamous non-small cell lung cancer (NSCLC).
Drugs in the Pipeline

sNDA Accepted, Priority Review Granted to Tarceva for Genetically Distinct NSCLC

Astellas announced that the FDA has accepted for filing a supplemental New Drug Application (sNDA) for Tarceva (erlotinib) for first-line use in people with locally advanced or metastatic non-small cell lung cancer (NSCLC) whose tumors have epidermal growth factor receptor (EGFR) activating mutations; the application has been granted Priority Review status.
Drugs in the Pipeline

FDA Fast Tracks Ganetespib for Non-Small Cell Lung Adenocarcinoma

The FDA has granted Fast Track designation to ganetespib (Synta Pharmaceuticals) to use combination with docetaxel for the treatment of patients with metastatic non-small lung adenocarcinoma who have progressed following one prior chemotherapy regimen.
Drugs in the Pipeline

Priority Review Granted to Afatinib for Advanced NSCLC

Boehringer Ingelheim announced that the New Drug Application (NDA) for afatinib has been accepted for filing and granted Priority Review by the FDA; the application is under review for the treatment of patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) with an epidermal growth factor receptor (EGFR) mutation as detected by an FDA-approved test.
Drugs in the Pipeline

Brigatinib NDA Accepted for FDA Review

ARIAD announced that the Food and Drug Administration (FDA) has accepted for review the New Drug Application (NDA) for brigatinib to treat patients with metastatic ALK+ non-small cell lung cancer (NSCLC) who have progressed on crizotinib.
Drugs in the Pipeline

Merck’s Lambrolizumab Receives Breakthrough Therapy Designation

The FDA has designated Merck's lambrolizumab (MK-3475) as Breakthrough Therapy for the treatment of patients with advanced melanoma. Lambrolizumab is an investigational antibody therapy targeting Programmed Death receptor.